Back to News
Market Impact: 0.2
JP Morgan Initiates Coverage of Arcus Biosciences at Overweight
Source: Nasdaq
Analyst InsightsHealthcare & Biotech
JP Morgan initiated coverage of Arcus Biosciences with an Overweight recommendation on October 14, 2026. The stock closed at $22.51 on October 13, a reported 7.29% decline over an unspecified period; the article text is truncated before giving further context.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.20
Ticker Sentiment
RCUS0.45
More News
- Earnings season is heating up. UBS thinks these stocks could beat expectations
- Why is GE Vernova stock sliding today?
- Citizens reiterates Kura Oncology stock rating on diabetes data
- JPMorgan initiates Standex stock with neutral on cyclical exposure
- Jim Cramer's top 10 things to watch in the stock market Wednesday
- A growing security premium threatens Saudi Arabia’s investment project